POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

Rhea-AI Summary

Pomdoctor (NASDAQ: POM) reported unaudited results for the six months ended June 30, 2025. Net revenue rose 16.2% to RMB174.5 million (US$24.4 million), driven by an 83.2% increase in online-pharmacy/Internet-hospital sales. Gross profit grew 16.3% to RMB28.3 million (US$4.0 million) with a stable gross margin of 16.2%. The company recorded a net loss of RMB19.9 million (US$2.8 million) and cash and cash equivalents were RMB5.7 million as of June 30, 2025. Pomdoctor completed its October 2025 IPO, raising gross proceeds of US$23,000,016.

Positive

• Net revenue +16.2% to RMB174.5 million
• Online-pharmacy/Internet hospital revenue +83.2%
• Gross profit +16.3% to RMB28.3 million
• Completed IPO raising US$23,000,016 gross proceeds

Negative

• Net loss widened to RMB19.9 million
• Net loss per share rose to RMB11.45
• Cash and cash equivalents low at RMB5.7 million
• Net cash used in operations increased to RMB15.0 million

Insights

Equity Analyst

Revenue grew while losses and cash use widened; growth driven by online pharmacy but margins and cash remain constrained.

Pomdoctor reported net revenue of RMB174.5 million for the six months ended June 30, 2025, a 16.2% increase year‑over‑year, led by an ~83% jump in its online pharmacy/Internet hospital activity to roughly RMB66.4 million in online pharmacy sales. Gross profit rose to RMB28.3 million with a stable overall gross margin of 16.2%, while Internet hospital margin declined to 40.5% and pharmaceutical supply chain margin fell to 1.1%.

Costs increased in key areas: sales and marketing rose to RMB27.8 million and general and administrative expense climbed to RMB10.5 million, partly from IPO‑related professional fees. The company recorded a larger net loss of RMB19.9 million versus RMB14.0 million a year earlier, and used RMB15.0 million in operating cash in the period; cash and cash equivalents were RMB5.7 million as of June 30, 2025.

Key dependencies and risks are explicit: sustaining higher‑margin Internet hospital sales while managing lower‑margin online pharmacy growth will determine margin trajectory, and available liquidity and operating cash flow will influence near‑term execution. Monitor cash and operating cash flow trends, gross margin by segment, and the use of proceeds from the completed IPO on October 9, 2025 over the next 12 months as concrete, trackable items.

GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to China's evolving healthcare landscape. These initiatives resulted in a 16.2% increase in net revenue, highlighted by growth of 83.2% in our online-pharmacy businesses.

At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of 16.2%. Gross profit increased 16.3% year over year, despite higher sales and marketing expenses, a larger contribution from lower-margin pharmacy products, and continued investments in customer acquisition. We prioritized retaining doctor resources while prudently reducing advertising spending, reinforcing the foundation for sustainable growth under a stable pharmaceutical supply chain.

Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."

First Half of Fiscal 2025 Financial Summary

• Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024.
• Gross profit increased by 16.3% from RMB24.3 million in the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
• Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025.
• Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB14.0 million for the six months ended June 30, 2024.
• Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

Unaudited Financial Results for the First Half of Fiscal 2025

• Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024, which was primarily attributable to the increase in the net revenues from Internet hospital. Net revenues from Internet hospital increased by 82.4% from RMB36.8 million in the six months ended June 30, 2024 to RMB67.2 million (US$9.4 million) in the six months ended June 30, 2025, primarily attributable to the increase in revenues generated from online pharmacy sales. In the first half of 2025, the Company strengthened its cooperation with pharmaceutical manufacturers to sell their products through its Internet hospital platform. As a result, revenue from the Company's online pharmacy sales increased from RMB36.3 million in the six months ended June 30, 2024 to RMB66.4 million (US$9.3 million) in the six months ended June 30, 2025.
• Cost of revenues increased by 16.2% from RMB125.8 million in the six months ended June 30, 2024 to RMB146.2 million (US$20.4 million) in the six months ended June 30, 2025, primarily due to the increase in cost of revenues in online pharmacy sales from RMB20.4 million in the six months ended June 30, 2024 to RMB40.0 million (US$5.6 million) in the six months ended June 30, 2025, which was in line with the increase in the Company's net revenues from Internet hospital.
• Gross profit increased by 16.3% from RMB24.3 million for the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
• Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025. The gross profit margin of the Company's Internet hospital decreased from 44.7% in the six months ended June 30, 2024 to 40.5% in the six months ended June 30, 2025, mainly due to the increase in the online pharmacy sales of products with lower gross profit margin. The gross profit margin of the Company's pharmaceutical supply chain business decreased from 6.9% in the six months ended June 30, 2024 to 1.1% in the six months ended June 30, 2025, which was primarily because the gross profit margin of the Company's pharmacy wholesale customers newly acquired in the six months ended June 30, 2024 was higher than that of customers in the six months ended June 30, 2025.
• Sales and marketing expenses increased by 11.6% from RMB24.9 million in the six months ended June 30, 2024 to RMB27.8 million (US$3.9 million) in the six months ended June 30, 2025, primarily due to higher service fees to doctors and increased staff costs in line with the growth in revenues from Internet hospital business, partially offset by a slight decrease in advertising and promotion costs resulting from a relatively stable pharmaceutical supply chain business.
• General and administrative expenses increased by 53.5% from RMB6.8 million in the six months ended June 30, 2024 to RMB10.5 million (US$1.5 million) in the six months ended June 30, 2025, primarily due to the increase in consultancy and professional service fees incurred in connection with the Company's initial public offering, partially offset by the decrease in expected credit loss recognized resulting from the efforts for collection of receivables.
• Research and development expense remained relatively stable at RMB1.5 million (US$0.2 million) for the six months ended June 30, 2024 and 2025.
• Impairment loss on long-lived assets recorded was RMB0.02 million and RMB2.0 million (US$0.3 million) for the six months ended June 30, 2024 and 2025, respectively.
• Loss from operation was RMB13.5 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB8.9 million for the six months ended June 30, 2024.
• Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB RMB14.0 million for the six months ended June 30, 2024.
• Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

Financial Condition

• Cash and cash equivalents of RMB5.7 million (US$0.8 million) as of June 30, 2025, compared to RMB7.7 million as of December 31, 2024.
• Net cash used in operating activities was RMB15.0 million (US$2.1 million) for the six months ended June 30, 2025, compared with RMB10.6 million for the six months ended June 30, 2024.
• Net cash used in investing activities was RMB512,200 (US$71,500) for the six months ended June 30, 2025, compared with RMB17,862 for the six months ended June 30, 2024.
• Net cash provided by financing activities was RMB13.6 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB16.6 million for the six months ended June 30, 2024.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.

Recent Development

On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company's ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

 

 

 

POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
		December 31, 2024				June 30, 2025				June 30, 2025
		RMB				RMB				US$
Assets
Current assets:
Cash and cash equivalents (including amounts of the consolidated VIEs of    RMB7,596,708 and RMB5,579,802 (US$778,910) as of December 31,    2024 and June 30, 2025, respectively)			7,651,695				5,746,989				802,249
Accounts receivable, net (including amounts of the consolidated VIEs of    RMB8,374,608 and RMB6,128,066 (US$855,445) as of December 31,    2024 and June 30, 2025, respectively)			8,374,608				6,128,066				855,445
Accounts receivable – a related party (including amounts of the    consolidated VIEs of RMB424,259 and RMB584,802 (US$81,635) as    of December 31, 2024 and June 30, 2025, respectively)			424,259				584,802				81,635
Amount due from related parties (including amounts of the consolidated    VIEs of RMB6,070,945 and RMB9,643,039 (US$1,346,117) as of    December 31, 2024 and June 30, 2025, respectively)			5,632,987				7,418,671				1,035,607
Inventories (including amounts of the consolidated VIEs of    RMB9,165,973 and RMB6,447,637 (US$900,055) as of December 31,    2024 and June 30, 2025, respectively)			9,165,973				6,447,637				900,055
Other receivables, net (including amounts of the consolidated VIEs of    RMB5,318,724 and RMB5,231,722 (US$730,319) as of December 31,    2024 and June 30, 2025, respectively)			5,318,724				5,231,722				730,319
Advances to suppliers (including amounts of the consolidated VIEs of    RMB929,167 and RMB2,921,966 (US$407,891) as of December 31,    2024 and June 30, 2025, respectively)			929,167				2,921,966				407,891
Total current assets			37,497,413				34,479,853				4,813,201
Non-current assets:
Property and equipment, net (including amounts of the consolidated VIEs    of RMB461,362 and RMB394,107 (US$55,015) as of December 31,    2024 and June 30, 2025, respectively)			461,362				394,107				55,015
Other non-current assets (including amounts of the consolidated VIEs of    RMB831,132 and RMB1,307,832 (US$182,566) as of December 31,    2024 and June 30, 2025, respectively)			831,132				1,307,832				182,566
Deferred offering costs (including amounts of the consolidated VIEs of    RMB7,437,679 and RMB6,007,339 (US$838,592) as of December 31,    2024 and June 30, 2025, respectively)			7,437,679				7,690,157				1,073,505
Total non-current assets			8,730,173				9,392,096				1,311,086
Total assets			46,227,586				43,871,949				6,124,287
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)
		December 31, 2024				June 30, 2025				June 30, 2025
		RMB				RMB				US$
Liabilities
Current liabilities:
Accounts payable (including amounts of the consolidated VIEs of    RMB25,320,486 and RMB25,164,804 (US$3,512,871) as of December    31, 2024 and June 30, 2025, respectively)			25,320,486				25,164,804				3,512,871
Accounts payable – a related party (including amounts of the consolidated    VIEs of RMB25,891 and RMB13,711 (US$1,914) as of December 31,    2024 and June 30, 2025, respectively)			25,891				13,711				1,914
Short-term bank loans (including amounts of the consolidated VIEs of    RMB34,958,333 and RMB34,708,333 (US$4,845,096) as of December    31, 2024 and June 30, 2025, respectively)			34,958,333				34,708,333				4,845,096
Long-term bank loans, current (including amounts of the consolidated    VIEs of RMB300,000 and RMB2,400,000 (US$335,027) as of    December 31, 2024 and June 30, 2025, respectively)			300,000				2,400,000				335,027
Long-term loans, current (including amounts of the consolidated VIEs of    RMB10,000,000 and RMB10,000,000 (US$1,395,946) as of December    31, 2024 and June 30, 2025, respectively)			10,000,000				10,000,000				1,395,946
Long-term loans from third parties, current (including amounts of the    consolidated VIEs of RMB2,320,082 and RMB2,295,082    (US$320,381) as of December 31, 2024 and June 30, 2025,    respectively)			2,320,082				2,295,082				320,381
Salary and welfare payable (including amounts of the consolidated VIEs       of RMB15,375,537 and RMB15,543,259 (US$2,169,755) as of    December 31, 2024 and June 30, 2025, respectively)			15,375,537				15,543,259				2,169,755
Advance from customers (including amounts of the consolidated VIEs of    RMB1,756,046 and RMB942,724 (US$131,599) as of December 31,    2024 and June 30, 2025, respectively)			1,756,046				942,724				131,599
Value added tax ("VAT") and other tax payable (including amounts of the    consolidated VIEs of RMB815,462 and RMB998,295 (US$139,357) as    of December 31, 2024 and June 30, 2025, respectively)			815,462				998,295				139,357
Other payables (including amounts of the consolidated VIEs of    RMB12,888,550 and RMB10,543,238 (US$1,471,777) as of December    31, 2024 and June 30, 2025, respectively)			12,888,750				10,543,438				1,471,806
Accrued liabilities (including amounts of the consolidated VIEs of    RMB9,712,966 and RMB11,564,144 (US$1,614,292) as of December    31, 2024 and June 30, 2025, respectively)			9,712,966				11,564,144				1,614,292
Short-term loans from third parties (including amounts of the consolidated    VIEs of RMB11,551,614 and RMB7,194,342 (US$1,004,291) as of    December 31, 2024 and June 30, 2025, respectively)			11,551,614				7,194,342				1,004,291
Loans from related parties, current (including amounts of the consolidated    VIEs of RMB13,821,875 and RMB33,194,670 (US$4,633,797) as of    December 31, 2024 and June 30, 2025, respectively)			13,821,875				33,194,670				4,633,797
Amount due to related parties (including amounts of the consolidated    VIEs of RMB36,829,010 and RMB42,403,073 (US$5,919,241) as of    December 31, 2024 and June 30, 2025, respectively)			36,829,010				42,403,073				5,919,241
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)
		December 31, 2024				June 30, 2025				June 30, 2025
		RMB				RMB				US$
Operating lease liabilities, current (including amounts of the    consolidated VIEs of RMB1,388,863 and RMB1,790,319    (US$249,919) as of December 31, 2024 and June 30, 2025,    respectively)			1,388,863				1,790,319				249,919
Other current liabilities (including amounts of the consolidated    VIEs of RMB2,080,556 and RMB237,580 (US$33,165) as of      December 31, 2024 and June 30, 2025, respectively)			2,080,556				237,580				33,165
Total current liabilities			179,145,471				198,993,774				27,778,457
Long-term bank loans, noncurrent (including amounts of the    consolidated VIEs of RMB8,400,000 and RMB5,700,000    (US$795,689) as of December 31, 2024 and June 30, 2025,    respectively)			8,400,000				5,700,000				795,689
Loans from related parties, noncurrent (including amounts of the    consolidated VIEs of RMB356,690,859 and RMB356,390,859    (US$49,750,246) as of December 31, 2024 and June 30, 2025,    respectively)			356,690,859				356,390,859				49,750,246
Operating lease liabilities, noncurrent (including amounts of the    consolidated VIEs of RMB1,672,218 and RMB2,346,664    (US$327,582) as of December 31, 2024 and June 30, 2025,    respectively)			1,672,218				2,346,664				327,582
Total non-current liabilities			366,763,077				364,437,523				50,873,517
Total liabilities			545,908,548				563,431,297				78,651,974
Commitments and contingencies			—				—				—
Mezzanine equity
Convertible redeemable preferred shares (US$0.0001 par value;    12,597,228 shares authorized, issued and outstanding as of    December 31, 2024 and June 30, 2025)			1,595,051,558				1,642,498,390				229,283,934
Redeemable non-controlling interests			168,671,234				173,630,137				24,237,833
Total mezzanine equity			1,763,722,792				1,816,128,527				253,521,767
Equity (deficit)
Class A ordinary shares (US$0.0001 par value; 485,360,730    shares authorized, 4,268,156 shares issued and outstanding as of    December 31, 2024 and June 30, 2025)			2,988				2,988				417
Class B Ordinary shares (US$0.0001 par value; 2,042,042 shares    authorized and outstanding as of December 31, 2024 and    June 30, 2025, respectively)			1,408				1,408				197
Subscription receivable			(1,608)				(1,608)				(224)
Accumulated deficit			(2,263,419,477)				(2,335,709,744)				(326,052,508)
Accumulated other comprehensive (loss) income			(5,231)				1,875				262
Total Pomdoctor Limited's shareholders' deficit			(2,263,421,920)				(2,335,705,081)				(326,051,856)
Noncontrolling interests			18,166				17,206				2,402
Total deficit			(2,263,403,754)				(2,335,687,875)				(326,049,454)
Total liabilities, mezzanine equity and deficit			46,227,586				43,871,949				6,124,287

 

 

 

POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
		For Six Months Ended June 30,
		2024				2025				2025
		RMB				RMB				US$
Net revenues – third parties			149,266,587				174,283,295				24,329,010
Net revenues – a related party			897,822				186,556				26,042
Net revenues			150,164,409				174,469,851				24,355,052
Cost of revenues			125,823,734				146,152,450				20,402,095
Gross profit			24,340,675				28,317,401				3,952,957
Operating expenses:
Sales and marketing expenses			24,884,898				27,761,736				3,875,389
General and administrative expenses			6,835,897				10,494,487				1,464,974
Research and development expenses			1,507,847				1,479,909				206,587
Impairment loss on long-lived assets			17,861				2,041,299				284,954
Total operating expenses			33,246,503				41,777,431				5,831,904
Loss from operations			(8,905,828)				(13,460,030)				(1,878,947)
Other income (expenses):
Other income			1,078,270				28,027				3,912
Other expense			(33,681)				(130,291)				(18,188)
Interest expense			(6,179,172)				(6,471,198)				(903,344)
Government grants			13,858				148,000				20,660
Total other expense, net			(5,120,725)				(6,425,462)				(896,960)
Loss before income tax			(14,026,553)				(19,885,492)				(2,775,907)
Income tax expense			—				—				—
Net loss			(14,026,553)				(19,885,492)				(2,775,907)
Accretion to redemption value of mezzanine equity			(52,695,272)				(52,405,735)				(7,315,559)
Less: Net income (loss) attributable to noncontrolling interests			27,639				(960)				(134)
Net loss attributable to the Pomdoctor Limited's ordinary    shareholders			(66,749,464)				(72,290,267)				(10,091,332)
Net loss			(14,026,553)				(19,885,492)				(2,775,907)
Other comprehensive (loss) income:
Total other comprehensive (loss) income			(3,970)				7,106				992
Total comprehensive loss			(14,030,523)				(19,878,386)				(2,774,915)
Accretion to redemption value of mezzanine equity			(52,695,272)				(52,405,735)				(7,315,559)
Less: comprehensive income (loss) attributable to noncontrolling    interests			27,639				(960)				(134)
Comprehensive loss attributable to the Pomdoctor Limited's    ordinary shareholders			(66,753,434)				(72,283,161)				(10,090,340)
Loss per share
Basic and diluted			(10.58)				(11.45)				(1.60)
Weighted average number of ordinary shares outstanding*
Basic and diluted			6,310,198				6,310,198				6,310,198
*  Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for     the Reorganization completed on August 8, 2024

 

 

 

POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
		For Six Months Ended June 30,
		2024				2025				2025
		RMB				RMB				US$
Net cash used in operating activities			(10,631,121)				(14,987,658)				(2,092,195)
Cash flows from investing activities:
Payment for purchase of property and equipment			(17,862)				(2,200)				(307)
Payment for long-term investment			—				(510,000)				(71,193)
Net cash used in investing activities			(17,862)				(512,200)				(71,500)
Cash flows from financing activities:
Loans from related parties			11,219,986				24,750,310				3,455,010
Repayment to related parties			(14,436,941)				(5,677,514)				(792,550)
Proceeds from short-term bank loans			37,000,000				29,000,000				4,048,244
Repayment of short-term bank loans			(19,300,000)				(29,250,000)				(4,083,143)
Repayment of long-term bank loans			(54,628)				(600,000)				(83,757)
Loans from third parties			8,759,366				1,600,000				223,351
Repayment to third parties			(4,968,912)				(5,982,272)				(835,093)
Payment for deferred offering cost			(1,656,745)				(252,478)				(35,245)
Net cash provided by financing activities			16,562,126				13,588,046				1,896,817
Effect of exchange rate changes			(3,970)				7,106				992
Net increase (decrease) in cash and cash equivalents and restricted cash			5,909,173				(1,904,706)				(265,886)
Cash and cash equivalents and restricted cash at beginning of the    period			6,805,099				7,651,695				1,068,135
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)
		For Six Months Ended June 30,
		2024				2025				2025
		RMB				RMB				US$
Including:
Cash and cash equivalents at beginning of the period			6,717,031				7,651,695				1,068,135
Restricted cash at beginning of the period			88,068				—				—
Cash and cash equivalents and restricted cash at end of the period			12,714,272				5,746,989				802,249
Including:
Cash and cash equivalents at end of the period			12,714,272				5,746,989				802,249
Supplemental disclosures of cash flows information:
Cash paid for interest expense			1,130,609				2,382,125				332,532
Supplemental disclosure of noncash investing and financing activities:
Operating lease right-of-use assets obtained in exchange for new operating     lease liabilities			—				2,039,099				284,647

 

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-first-half-of-fiscal-2025-unaudited-financial-results-302632067.html

SOURCE POMDOCTOR LIMITED

FAQ

What were Pomdoctor (POM) net revenues for H1 fiscal 2025?

Pomdoctor reported RMB174.5 million (US$24.4 million) in net revenues for the six months ended June 30, 2025, up 16.2% year-over-year.

How much did Pomdoctor's online pharmacy sales grow in H1 2025 (POM)?

Online pharmacy revenues increased by about 83.2%, driving most of the Internet-hospital revenue gain.

What was Pomdoctor's (POM) net loss and EPS in H1 2025?

Net loss was RMB19.9 million (US$2.8 million) and net loss per share was RMB11.45 for the six months ended June 30, 2025.

How strong is Pomdoctor's cash position after H1 2025?

Cash and cash equivalents were RMB5.7 million as of June 30, 2025.

How did Pomdoctor (POM) finance operations after H1 2025?

Pomdoctor completed an IPO in October 2025, generating US$23,000,016 gross proceeds from ADS sales.

Did Pomdoctor (POM) maintain gross margins in H1 2025?

Overall gross margin stayed at 16.2%, though Internet-hospital margin fell to 40.5% and pharmaceutical supply margin declined to 1.1%.